Cesium carbonate → 7-(Cyclopropanecarboxamido)-3-(5-fluoro-4-methylpyridin-3-yl)-2,6-naphthyridine 2-oxide

Temperatur

100 °C

A mixture of chloro[2-(dicyclohexylphosphino)-3,6-dimethoxy-2′-4′-6′-tri-1-propyl-1,1′-biphenyl][2-(2-aminoethyl)phenyl]palladium(II) (28 mg, 0.035 mmol), cesium carbonate (227 mg, 0.69 mmol), 2-(dicyclohexylphosphino)3,6-dimethoxy-2′,4′,6′-triisopropyl-1,1′-biphenyl (19 mg, 0.035 mmol), 7-chloro-3-(5-fluoro-4-methylpyridin-3-yl)-2,6-naphthyridine 2-oxide (100 mg, 0.35 mmol), and cyclopropanecarboxamide (59 mg, 0.69 mmol) in dioxane (2 mL) was heated at 100° C. for 8 hours in a vial sealed with a Teflon cap. The reaction mixture was diluted with dichloromethane (50 mL) and methanol (5 mL), filtered over Celite, and concentrated in vacuo to provide a residue that was purified by reverse phase HPLC purification (5-85% ACN in water w/0.1% NH4OH, 14 min) Desired fractions were combined and evaporated in vacuo to afford the title compound as a white solid. 1H NMR (400 MHz, DMSO) δ 11.12 (s, 1H), 9.14 (s, 2H), 8.63 (s, 1H), 8.44 (s, 1H), 8.39 (s, 1H), 8.24 (s, 1H), 2.12 (d, J=1.5 Hz, 3H), 2.08 (m, 1H), 0.86 (m, 4H). LCMS (Method E): RT=3.626 min, M+H+=339.2.

1. customcap
2. filtrationfiltered over Celite
3. concentrationconcentrated in vacuo
4. customto provide a residue that
5. customwas purified by reverse phase HPLC purification (5-85% ACN in water w/0.1% NH4OH, 14 min) Desired fractions
6. customevaporated in vacuo

ORD-Eintrag

ord-b28a3a5791b04bc18793d0e8846d8470

Quelldatensatz

uspto-grants-2015_12

DOI

10.6084/m9.figshare.5104873.v1

Patentnummer

US09206175B2